FutuRx
Bernhard Kirschbaum, Ph.D., studied and spent his early career as a researcher in biochemistry and physiological chemistry at the University of Konstanz, Germany, receiving his Ph.D. in 1989. He moved on to work at the Rockefeller University in New York and the Pasteur Institute in Paris. Subsequently, he joined the pharmaceutical industry where he covered a broad range of technological and disease areas. Before joining various biotech companies as chairman and board member, respectively, he was head of Global Research and Early Development at Merck Serono. In this role, he was a member of the Pharmaceutical Executive Committee. Prior to joining Merck KGaA in 2005, he was Vice President Discovery Research, Global Head of Therapeutic Domains “Thrombosis & Angiogenesis” for Sanofi-Aventis. He also worked for Aventis, Hoechst Marion Roussel in various senior positions.
This person is not in the org chart
This person is not in any offices
FutuRx
FutuRx is a biotech incubator founded by three leading global healthcare players. FutuRx leverages its access to the Israeli biotech industry, and to leading research institutes in Israel and worldwide, to identify and develop highly innovative technologies. Experts at Takeda, J&J, and OrbiMed are deeply involved in the project selection process and during the incubator period of each company. The result is a clear impact on the efficient translation of innovative research to clinically meaningful products.